首页> 美国卫生研究院文献>Oncology Letters >Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells
【2h】

Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells

机译:赖氨酸特异性脱甲基酶1的抑制作用阻止卵巢癌细胞的增殖并介导顺铂敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lysine-specific demethylase 1 (LSD1) functions as a transcriptional coregulator by modulating histone methylation and has been associated with numerous high-risk cancers. Previously, our group and others identified LSD1 as an upregulated gene in ovarian cancer, and reported that the upregulation of LSD1 was associated with poor prognosis of patients with ovarian cancer. However, the role of LSD1 in ovarian cancer requires further investigation. The present study revealed that the overexpression of LSD1 significantly promoted the proliferation of SKOV3 ovarian cancer cells, while knockdown of LSD1 markedly inhibited cell proliferation and potentiated cisplatin-induced cell apoptosis, supporting LSD1 as an oncogenic protein in ovarian cancer. Mechanistic studies have indicated that LSD1 modulates the expression of cyclin dependent kinase inhibitor 1, Survivin, B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X genes, which are known regulators of cell proliferation. Furthermore, LSD1 knockdown plus cisplatin synergistically impaired cell migration via the induction of the epithelial marker E-cadherin and inhibition of the mesenchymal markers, snail family transcriptional repressor 1 and Vimentin. These data of the present study indicated LSD1 as a potential regulator of ovarian cancer cell progression and suggested an unfavorable role of LSD1 in cisplatin-based regimens.
机译:赖氨酸特异性脱甲基酶1(LSD1)通过调节组蛋白甲基化而起转录共调节剂的作用,并已与许多高危癌症相关。先前,我们的研究小组和其他人将LSD1鉴定为卵巢癌的上调基因,并报道LSD1的上调与卵巢癌患者的预后不良有关。然而,LSD1在卵巢癌中的作用需要进一步研究。本研究表明,LSD1的过表达显着促进了SKOV3卵巢癌细胞的增殖,而敲低LSD1则显着抑制了细胞的增殖并增强了顺铂诱导的细胞凋亡,从而支持LSD1作为卵巢癌的致癌蛋白。机理研究表明,LSD1调节细胞周期蛋白依赖性激酶抑制剂1,Survivin,B细胞淋巴瘤2(Bcl-2)和Bcl-2相关X基因的表达,它们是细胞增殖的调节因子。此外,LSD1敲低加顺铂通过诱导上皮标记E-钙黏着蛋白和抑制间充质标记,蜗牛家族转录阻遏物1和波形蛋白协同抑制细胞迁移。本研究的这些数据表明LSD1是卵巢癌细胞发展的潜在调节剂,并暗示了LSD1在基于顺铂的治疗方案中的不利作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号